Literature DB >> 11096676

Helex Septal Occluder for Closure of Atrial Septal Defects.

.   

Abstract

The HELEX Septal Occluder (W.L. Gore and Associates, Flagstaff, AZ) is a new device with many desirable characteristics. These include direct placement of the delivery catheter across the septal defect without the need for a long sheath; rounded, flexible and atraumatic shape; easy deployment while maintaining the ability to withdraw the device back into the delivery system at any time prior to release; safety cord to allow for removal of the device even after release from the formed elements of the delivery system; and highly biocompatible expanded polytetrafluoroethylene (ePTFE) covering. The design of the device has been thoroughly tested by computer modeling, in vitro testing, and in vivo evaluations in an animal model of atrial septal defect (ASD). Early human experience in Europe for ASD and patent foramen ovale (PFO) indications has been encouraging. Food and Drug Administration (FDA) trials in the United States are anticipated this year.

Entities:  

Year:  2000        PMID: 11096676

Source DB:  PubMed          Journal:  Curr Interv Cardiol Rep        ISSN: 1523-3839


  4 in total

1.  Use of the transseptal puncture in transcatheter closure of long tunnel-type patent foramen ovale.

Authors:  C J McMahon; H G El Said; C E Mullins
Journal:  Heart       Date:  2002-08       Impact factor: 5.994

Review 2.  [Interventional closure of atrial septal defects, patent oval foramen and ventricular septal defects].

Authors:  Marius Hornung; Jennifer Franke; Dani Id; Horst Sievert
Journal:  Herz       Date:  2015-08       Impact factor: 1.443

3.  First experience with the 2005 modified Gore Helex ASD occluder system.

Authors:  R Kozlik-Feldmann; R Dalla Pozza; U Römer; T Rampp; P Bernasconi; S Däbritz; H Netz
Journal:  Clin Res Cardiol       Date:  2006-07-20       Impact factor: 5.460

4.  Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients.

Authors:  G Fischer; J Stieh; A Uebing; U Hoffmann; G Morf; H H Kramer
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.